DXCM Stock Overview
A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
DexCom, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$75.24 |
| 52 Week High | US$142.00 |
| 52 Week Low | US$62.34 |
| Beta | 1.17 |
| 11 Month Change | 3.62% |
| 3 Month Change | 4.10% |
| 1 Year Change | -32.09% |
| 33 Year Change | -49.72% |
| 5 Year Change | 32.27% |
| Change since IPO | 2,463.54% |
Recent News & Updates
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?
Nov 08
DexCom Growing Into Its Valuation, But Still No Bargain
Oct 25DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings
Oct 21DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships
Oct 16Recent updates
Are Investors Undervaluing DexCom, Inc. (NASDAQ:DXCM) By 44%?
Nov 08DexCom Growing Into Its Valuation, But Still No Bargain
Oct 25DexCom, Inc.'s (NASDAQ:DXCM) Price In Tune With Earnings
Oct 21DexCom Q3 Preview: Walking On Eggshells With Its Channel Relationships
Oct 16These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Sep 30DexCom: Investors Discounting Long CGM Growth Runway
Sep 19We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)
Sep 16DexCom Q2 Earnings: Traditional Market Overreaction
Aug 07Is Now The Time To Look At Buying DexCom, Inc. (NASDAQ:DXCM)?
Jul 26DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures
Jul 26Why Investors Shouldn't Be Surprised By DexCom, Inc.'s (NASDAQ:DXCM) P/E
Jul 12DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
Jul 03DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Jun 28Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Jun 03Dexcom: Positive Catalysts Ahead To Support Growth
May 13If EPS Growth Is Important To You, DexCom (NASDAQ:DXCM) Presents An Opportunity
May 07DexCom: Attractive Discount After Strong Earnings Results
May 06Returns At DexCom (NASDAQ:DXCM) Are On The Way Up
Apr 25Why We're Not Concerned About DexCom, Inc.'s (NASDAQ:DXCM) Share Price
Apr 12DexCom Is Pricey For A Reason - Its Growth Story Reflects That
Apr 11Is DexCom (NASDAQ:DXCM) Using Too Much Debt?
Mar 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Mar 04DexCom: A Wealth Compounder In Healthcare
Feb 14DexCom: Stelo Stellar Outlook
Jan 17DexCom (NASDAQ:DXCM) Is Experiencing Growth In Returns On Capital
Jan 15DexCom, Inc. (NASDAQ:DXCM) Not Lagging Industry On Growth Or Pricing
Jan 01DexCom (NASDAQ:DXCM) Seems To Use Debt Rather Sparingly
Dec 18A Look At The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Dec 05At US$109, Is It Time To Put DexCom, Inc. (NASDAQ:DXCM) On Your Watch List?
Nov 21DexCom (NASDAQ:DXCM) Is Looking To Continue Growing Its Returns On Capital
Sep 28DexCom (NASDAQ:DXCM) Could Easily Take On More Debt
Sep 13Calculating The Fair Value Of DexCom, Inc. (NASDAQ:DXCM)
Aug 29Should You Think About Buying DexCom, Inc. (NASDAQ:DXCM) Now?
Aug 14DexCom (NASDAQ:DXCM) Has A Rock Solid Balance Sheet
Jun 05There's Been No Shortage Of Growth Recently For DexCom's (NASDAQ:DXCM) Returns On Capital
May 16Do DexCom's (NASDAQ:DXCM) Earnings Warrant Your Attention?
Mar 21These 4 Measures Indicate That DexCom (NASDAQ:DXCM) Is Using Debt Safely
Mar 03DexCom (NASDAQ:DXCM) Is Doing The Right Things To Multiply Its Share Price
Feb 13Shareholder Returns
| DXCM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.7% | -0.4% | -1.0% |
| 1Y | -32.1% | 20.3% | 30.3% |
Return vs Industry: DXCM underperformed the US Medical Equipment industry which returned 20.3% over the past year.
Return vs Market: DXCM underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| DXCM volatility | |
|---|---|
| DXCM Average Weekly Movement | 4.4% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DXCM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DXCM's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 9,550 | Kevin Sayer | www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
DexCom, Inc. Fundamentals Summary
| DXCM fundamental statistics | |
|---|---|
| Market cap | US$29.25b |
| Earnings (TTM) | US$680.80m |
| Revenue (TTM) | US$3.95b |
43.2x
P/E Ratio7.4x
P/S RatioIs DXCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXCM income statement (TTM) | |
|---|---|
| Revenue | US$3.95b |
| Cost of Revenue | US$1.52b |
| Gross Profit | US$2.44b |
| Other Expenses | US$1.76b |
| Earnings | US$680.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.74 |
| Gross Margin | 61.68% |
| Net Profit Margin | 17.22% |
| Debt/Equity Ratio | 123.3% |
How did DXCM perform over the long term?
See historical performance and comparison